Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.
WARNING LETTER
•Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.•March 22, 2024

Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd. – FDA Warning Letter, Mar 22, 2024

Record Details

The FDA issued a Warning Letter to Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd. following an inspection from March 18-22, 2024, which documented significant CGMP violations and inspection limitations/refusals.

The firm limited and refused the inspection by: * **Limiting Access to Records:** Providing unreasonably redacted manufacturing records (process validation reports, batch records, equipment qualification reports) and incomplete CAPA lists. * **Limiting Photography:** Prohibiting investigators from photographing dirty and disrepaired filling machines (ID-192, ID-197). * **Limiting Access to Areas:** Denying access to a manufacturing room where specific operations were performed.

These actions render the firm's drugs adulterated under section 501(j) of the FD&C Act.

Additional CGMP violations include: 1. **Failure to Clean and Maintain Equipment (21 CFR 211.67(a)):** Investigators observed residues and disrepair on filling machines (ID-192, ID-197) despite being marked "clean." The firm's response regarding revised cleaning procedures and repairs was deemed inadequate, lacking a comprehensive CAPA plan for oversight and a retrospective assessment of cleaning effectiveness. 2. **Failure to Establish Adequate Production and Process Controls (21 CFR 211.100(a)):** The

Company
Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.
Inspection date
March 22, 2024
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 371d4f60-a959-4d7b-9b6b-1f65f960c425

Violation Codes10
21 CFR 21021 CFR 21121 U.S.C. 351(j)21 CFR 211.67(a)21 CFR 211.100(a)21 CFR 211.160(a)21 CFR 211.166FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.
  • 483 - 2024-03-22March 22, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.